릴레이 테라퓨틱스(RLAY)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $18.91 (-1.46%), 시가총액 $2.34B, 52주 최저~최고 $2.85 ~ $16.80.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a recep
릴레이 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
릴레이 테라퓨틱스의 현재 주가는 $18.91 (-1.46%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
릴레이 테라퓨틱스의 시가총액은 약 $2.34B입니다.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted o